Company Profile

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Companyâ€™s Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C1, a rare and fatal genetic disease, (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimerâ€™s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimerâ€™s disease (NCT03624842).

Employees

Sector

Pharmaceuticals

More about the company

10-29	Rafael Holdings Inc And Cyclo Therapeutics LLC Submit New Drug Application To FDA For Trappsol Cyclo Remibetadex For Treatment Of Niemann-Pick Disease Type C	CI
04-22	Cyclo Therapeutics Enters into Exclusive Licensing Agreement with Massachusetts Institute of Technology	CI
27/08/25	Cyclo Therapeutics Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism	CI
18/07/25	Cyclo Therapeutics, Inc. Announces Resignation of N. Scott Fine as Chief Executive Officer, Effective July 31, 2025	CI
18/06/25	Cyclo Therapeutics, Inc. Announces Continuation of Its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1	CI
27/03/25	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) dropped from S&P TMI Index	CI
26/03/25	Rafael Closes Merger With Cyclo Therapeutics	MT
26/03/25	Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals	RE
25/03/25	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) dropped from NASDAQ Composite Index	CI
24/03/25	Rafael Holdings, Inc. completed the acquisition of remaining 33.3% stake of Cyclo Therapeutics, Inc. from Armistice Capital Master Fund Ltd., fund managed by Armistice Capital LLC, Novit, L.P., Hercules Capital, Inc. (NYSE: HTGC) and others.	CI
06/03/25	Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings	RE
05/03/25	Cyclo Therapeutics, Inc. announced that it has received $2.5 million in funding from Rafael Holdings, Inc.	CI
07/02/25	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC(TM) Open-Label Sub-Study in Patients (< 3 Years Old)	RE

27/08/24	Maxim Downgrades Cyclo Therapeutics to Hold From Buy	MT
23/08/24	HC Wainwright Downgrades Cyclo Therapeutics to Neutral From Buy	MT
01/05/24	HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target	MT
27/09/23	Maxim Upgrades Cyclo Therapeutics to Buy From Hold With $4 Price Target	MT
20/03/23	Maxim Group Downgrades Cyclo Therapeutics to Hold From Buy	MT

26/03/25	Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals	AQ
20/02/25	CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH	BU
10/02/25	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing phase 3 TransportNPC Open-Label Sub-Study in Patients	AQ
07/02/25	Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)	BU
15/01/25	Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium 2025	AQ

3 years	0.55	2.12
5 years	0.55	8.3
10 years	0.55	118

Manager	Title	Age	Since
Charles Strattan CEO	Chief Executive Officer	80	22/09/2013
Jeffrey Tate CEO	Chief Executive Officer	68	03/07/2014

Cyclo Therapeutics, Inc. Share Price

Stocks

CYTH

US23254X2018

Pharmaceuticals

Latest news: Cyclo Therapeutics, Inc.

Analysts' recommendations: Cyclo Therapeutics, Inc.

Press Releases: Cyclo Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Cyclo Therapeutics, Inc.

Latest insider transactions

Other Pharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/02/25	Vivien Wong	Free	Director	25,140	0.0879%
27/02/25	Randall Toig	Free	Director	33,311	0.1164%
27/02/25	F. Ostronic	Free	Director	70,329	0.2458%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYCLO THERAPEUTICS, INC.	+1.39%	-.--%	-	-	20.73M
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.91%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+84.17%	658B
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+108.88%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+55.81%	+72.50%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.59%	369B
NOVARTIS AG	+1.12%	+4.52%	+34.76%	+58.24%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.95%	+36.20%	290B
AMGEN INC.	+1.15%	+6.09%	+56.15%	+82.25%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+117.32%	212B
Average	+2.01%	+5.90%	+46.58%	+84.56%	473.55B
Weighted average by Cap.	+2.01%	+6.60%	+50.51%	+100.44%